RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $44 price target.
July 11, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Viridian Therapeutics and maintained a $44 price target.
The reiteration of an Outperform rating by RBC Capital indicates a positive outlook for Viridian Therapeutics. The maintained price target of $44 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100